Efeito anti-hipertensivo de urapidil em hipertensäo arterial leve a moderada: estudo randomizado, duplo-cego, contra placebo / Antihypertensive effect of urapidil in mild to moderate arterial hypertension: randomized, double-blind versus placebo study
Arq. bras. cardiol
; 61(2): 127-130, ago. 1993. tab
Artigo
em Português
| LILACS
| ID: lil-148737
Biblioteca responsável:
BR1.1
ABSTRACT
PURPOSE--To evaluate the efficacy and tolerability of urapidil (a new central and peripheral antihypertensive agent) in patients with mild to moderate essential hypertension. METHODS--Thirty-one patients were randomized, double-blindly, to receive either placebo (15 patients) or urapidil (16 patients) for 3 months. The initial dose of urapidil was 30mg twice daily, per oral. The dose was increased progressively till achievement of good blood pressure control or the dose of 60mg three times a day. RESULTS--Seventy percent of the patients on urapidil group responded to therapy against 30 per cent on the placebo group. There were 3 cases of hypertensive crises (2 on urapidil and 1 on placebo) on the early therapy. The adverse events with urapidil were unfrequent and the most common were headache and dizziness. There were no modification on blood sugar and lipids level. CONCLUSION--Urapidil appears to be a safe antihypertensive agent in the treatment of mild to moderate essential hypertension. It also did not demonstrate any clinical effect on the carbohydrates and lipids profile
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Piperazinas
/
Pressão Arterial
/
Hipertensão
/
Anti-Hipertensivos
Tipo de estudo:
Ensaio clínico controlado
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Português
Revista:
Arq. bras. cardiol
Assunto da revista:
Cardiologia
Ano de publicação:
1993
Tipo de documento:
Artigo
